^
    Back
    Association details:
    Biomarker:AKT1 E17K
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Mol Cancer Res
    Title:

    AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants

    Excerpt:
    Both patients with AKT1 E17K alone had primary resistance to cetuximab, whereas 7 of 8 patients with PIK3CA mutation alone experienced tumor shrinkage or stability with anti-EGFR therapy.
    DOI:
    10.1158/1541-7786.MCR-15-0062-T
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Oncotarget
    Title:

    Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.

    Excerpt:
    Overall, tumors harboring mutations in the KRAS-NRAS-BRAF axis responded poorly to cetuximab-based treatment….tumor A00021 had both AKT1 E17K (27.9%) and BRAF G469A (19.7%) mutations, and tumor A00026 had both BRAF D594G (26.7%) and PIK3CA E542K (15.6%) mutations....tumor A00021 had both AKT1 E17K (27.9%) and BRAF G469A (19.7%) mutations, and tumor A00026 had both BRAF D594G (26.7%) and PIK3CA E542K (15.6%) mutations...Such differences in mutant allele frequencies implies complex intra-tumor heterogeneity, which may also contribute to the lack of response to cetuximab.
    DOI:
    https://doi.org/10.18632/oncotarget.8076